Norbrook Laboratories ltd

Business Insights, PHARMA TECH

KSQ Therapeutics | January 30, 2023

KSQ Therapeutics, a leading clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases, recently announced that Ono Pharmaceutical (ONO) has acquired multiple research-stage DNA damage response (DDR) programs. The programs were identified using KSQ's CRISPRomics platform technology. All of the programs are new and have the potential to be first-in-class therapies. ONO's Discovery & Research Executive Director/ Senior Executive O...

News-Medical.Net | March 02, 2020

A new Commentary identifies three actionable challenges for translating pharmacomicrobiomics to personalized medicine in 2020.Pharmacomicrobiomics is the study of how microbiome variations within and between individuals affect drug action, efficacy, and toxicity. This personalized medicine horizon scanning is featured in OMICS: A Journal of Integrative Biology, the peer-reviewed interdisciplinary journal published by Mary Ann Liebert, Inc., publishers. Ramy Aziz and Marwa ElRakaiby, Cairo Univer...

pharma news | January 14, 2020

Roche missed out on acquiring next-generation sequencing (NGS) specialist Illumina via a hostile takeover a few years back, but has compensated for that with a 15-year alliance focusing on cancer genomics. The new deal comes after Illumina called off a $1.2 billion merger agreement with another NGS player – Pacific Biosciences or PacBio – after concluding it would be unlikely to make it past antitrust regulators in the US and UK. Illumina is thought to have around 80% of the DNA sequ...

Views and Analysis

Regeneron Pharmaceuticals, Inc | January 31, 2022

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending to extend the approval of Dupixent® (dupilumab) in the European Union (EU) to include add-on maintenance treatment for children aged 6 to 11 years with severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) who are inadequate...